{
    "id": 94,
    "premise": "none",
    "hypothesis": "Combination vemurafenib and MEK inhibitor unavailable for patient.",
    "label": "entailment",
    "explanation": "MEK inhibitors unavailable in patients country.\nCombination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Combination vemurafenib and MEK inhibitor unavailable for patient.",
        "refined explanation": "MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. This means that if MEK inhibitors cannot be accessed, the patient cannot receive the combination treatment.",
        "refined iteration": 10,
        "history explanation": [
            "0 iteration: MEK inhibitors unavailable in patients country.\nCombination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy.",
            "1 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient.\nCombination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy.",
            "2 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient.\nThe combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy, but this is not applicable if MEK inhibitors are unavailable in the patient's country.",
            "3 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient.\nThe combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy, but this potential benefit is not applicable if MEK inhibitors are unavailable in the patient's country.",
            "4 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient.",
            "5 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient.",
            "6 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient.",
            "7 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient.\nIf a specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable in the patient's country, then it is unavailable for the patient.",
            "8 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient.",
            "9 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient.",
            "10 iteration: MEK inhibitors are unavailable in the patient's country.\nIf MEK inhibitors are unavailable in the patient's country, then any treatment involving a MEK inhibitor is unavailable for the patient.\nIf MEK inhibitors are unavailable in the patient's country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. This means that if MEK inhibitors cannot be accessed, the patient cannot receive the combination treatment."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* According to Explanation 1, MEK inhibitors are unavailable in the patient\\'s country. *)\\n(* This implies that the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.8379430770874, 'proof tactics': [], 'code': 'theory clinical_94_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationVemurafenib :: \"entity \u21d2 bool\"\\n  Results :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  BetterThan :: \"entity \u21d2 entity \u21d2 bool\"\\n  VemurafenibMonotherapy :: \"entity\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors unavailable in patients country. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. CombinationVemurafenib x \u2227 MEKInhibitor y \u2227 Results z \u2227 Yield e \u2227 Agent e x \u2227 Patient e z \u2227 BetterThan z VemurafenibMonotherapy\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"CombinationVemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient. *)\\n  shows \"\u2200x y. CombinationVemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the known information, we have a combination of vemurafenib and a MEK inhibitor. *)\\n  from asm have \"CombinationVemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* According to Explanation 1, MEK inhibitors are unavailable in the patient\\'s country. *)\\n  (* This implies that the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nNot(A)\\nNot(MEK inhibitors are unavailable in the patient's country)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(MEK inhibitors are unavailable in the patient's country), Not(combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy))\\n--------\\n\\nDerived Implications:\\nImplies(A, Not(B))\\nImplies(MEK inhibitors are unavailable in the patient's country, Not(combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy))\\n--------\\nImplies(B, Not(A))\\nImplies(combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy, Not(MEK inhibitors are unavailable in the patient's country))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy), Not(MEK inhibitors are unavailable in the patient's country))\\n--------\\nImplies(B, Not(B))\\nImplies(combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy, Not(combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy))\\n--------\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, combination of vemurafenib and a MEK inhibitor yields better results than vemurafenib monotherapy)\\n--------\\n\"}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n(* This is represented by Implies(A, B). *)\\n(* Since we are given MEKInhibitor y, we can use explanation_2 to infer UnavailableFor x y. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.86531114578247, 'proof tactics': [], 'code': 'theory clinical_94_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationVemurafenib :: \"entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Results :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  BetterThan :: \"entity \u21d2 entity \u21d2 bool\"\\n  VemurafenibMonotherapy :: \"entity\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u2227 UnavailableIn x y) \u27f6 (CombinationVemurafenib z \u2227 UnavailableFor z x)\"\\n\\n(* Explanation 3: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. CombinationVemurafenib x \u2227 MEKInhibitor y \u2227 Results z \u2227 Yield e \u2227 Agent e x \u2227 Patient e z \u2227 BetterThan z VemurafenibMonotherapy\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"CombinationVemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. CombinationVemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the known information, we have CombinationVemurafenib x and MEKInhibitor y. *)\\n  from asm have \"CombinationVemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 2 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  (* This is represented by Implies(A, B). *)\\n  (* Since we are given MEKInhibitor y, we can use explanation_2 to infer UnavailableFor x y. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: the combination of vemurafenib and a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: the combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(C, Not(A))\\nImplies(the combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy, Not(MEK inhibitors are unavailable in the patient's country))\\n--------\\n\\nDerived Implications:\\n\"}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n(* Explanation 2 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n(* Using the logical relation Implies(A, B), we can infer that the combination is unavailable for the patient. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.16477918624878, 'proof tactics': [], 'code': 'theory clinical_94_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Results :: \"entity \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  BetterThan :: \"entity \u21d2 entity \u21d2 bool\"\\n  NotApplicable :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u2227 UnavailableIn x y) \u27f6 (Combination z \u2227 Vemurafenib z \u2227 MEKInhibitor x \u27f6 UnavailableFor z x)\"\\n\\n(* Explanation 3: The combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy, but this is not applicable if MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w. (Combination x \u2227 Vemurafenib x \u2227 MEKInhibitor y \u2227 Results z \u2227 Monotherapy w \u2227 Yield e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 BetterThan z w) \u2227 (MEKInhibitor y \u2227 Country z \u2227 UnavailableIn y z \u27f6 NotApplicable x)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. Combination x \u2227 Vemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n  (* Explanation 2 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  (* Using the logical relation Implies(A, B), we can infer that the combination is unavailable for the patient. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: the combination of vemurafenib and a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: the combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, Not(C))\\nImplies(MEK inhibitors are unavailable in the patient's country, Not(the combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy))\\n--------\\n\\nDerived Implications:\\n\"}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n(* Explanation 2 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient. *)\\n(* Using the logical relation Implies(A, B), we can infer that the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.29353094100952, 'proof tactics': [], 'code': 'theory clinical_94_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationVemurafenib :: \"entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  BetterResults :: \"entity \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  PotentialBenefit :: \"event \u21d2 bool\"\\n  NotApplicable :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (Treatment z \u2227 Involves z x \u2227 CombinationVemurafenib z \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 3: The combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy, but this potential benefit is not applicable if MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z e1 e2. (CombinationVemurafenib x \u2227 MEKInhibitor y \u2227 Yield e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 BetterResults z \u2227 Monotherapy y \u27f6 PotentialBenefit e2 \u2227 NotApplicable e2 \u2227 (MEKInhibitor y \u2227 Country z \u27f6 UnavailableIn y z))\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"CombinationVemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. CombinationVemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the assumption, we have known information about the combination of vemurafenib and MEK inhibitor. *)\\n  from asm have \"CombinationVemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n  (* Explanation 2 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient. *)\\n  (* Using the logical relation Implies(A, B), we can infer that the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient (from Explanatory Sentence 2)\\nC: the combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy (from Explanatory Sentence 3)\\nD: this potential benefit is not applicable (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient)\\n--------\\nImplies(A, D)\\nImplies(MEK inhibitors are unavailable in the patient's country, this potential benefit is not applicable)\\n--------\\n\\nDerived Implications:\\n\"}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(A, C), which states that if MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n(* Explanation 3 directly supports this logical relation. *)\\n(* Since we have CombinationVemurafenib x and MEKInhibitor y, we can apply explanation_3 to infer UnavailableFor x y. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.21885848045349, 'proof tactics': [], 'code': 'theory clinical_94_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationVemurafenib :: \"entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor, including the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (Treatment z \u2227 Involves z x \u2227 CombinationVemurafenib z \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 3: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (CombinationVemurafenib z \u2227 MEKInhibitor z \u27f6 UnavailableFor z y)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"CombinationVemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. CombinationVemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the assumption, we have known information about the combination of vemurafenib and MEK inhibitor. *)\\n  from asm have \"CombinationVemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* There is a logical relation Implies(A, C), which states that if MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  (* Explanation 3 directly supports this logical relation. *)\\n  (* Since we have CombinationVemurafenib x and MEKInhibitor y, we can apply explanation_3 to infer UnavailableFor x y. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: the combination of vemurafenib and a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2 and 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, C)\\nImplies(MEK inhibitors are unavailable in the patient's country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\n\\nDerived Implications:\\n\"}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n(* Explanation 3 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n(* Using the logical relation Implies(A, C), we can infer that the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 104.42130398750305, 'proof tactics': [], 'code': 'theory clinical_94_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u2227 UnavailableIn x y) \u27f6 (Treatment z \u2227 Involves z x \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 3: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u2227 UnavailableIn x y) \u27f6 (Vemurafenib z \u2227 Combination z x \u27f6 UnavailableFor z y)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Vemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. Vemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the premise, we have known information about Vemurafenib and MEKInhibitor. *)\\n  from asm have \"Vemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n  (* Explanation 3 provides a logical relation: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  (* Using the logical relation Implies(A, C), we can infer that the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: the combination of vemurafenib and a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, C)\\nImplies(MEK inhibitors are unavailable in the patient's country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\n\\nDerived Implications:\\n\"}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n(* Explanation 3 provides a logical relation Implies(A, C), which states that if MEK inhibitors are unavailable in the patient\\'s country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient. *)\\n(* Since we have Vemurafenib x and MEKInhibitor y, we can apply this logical relation. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.42676639556885, 'proof tactics': [], 'code': 'theory clinical_94_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationTreatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u2227 UnavailableIn x y) \u27f6 (Treatment z \u2227 Involves z x \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 3: If MEK inhibitors are unavailable in the patient\\'s country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w. (MEKInhibitor x \u2227 Country y \u2227 UnavailableIn x y) \u27f6 (CombinationTreatment z \u2227 Involves z x \u2227 Vemurafenib w \u2227 Involves z w \u27f6 UnavailableFor z y)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Vemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. Vemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the premise, we have known information about Vemurafenib and MEKInhibitor. *)\\n  from asm have \"Vemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 1 states that MEK inhibitors are unavailable in the patient\\'s country. *)\\n  (* Explanation 3 provides a logical relation Implies(A, C), which states that if MEK inhibitors are unavailable in the patient\\'s country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient. *)\\n  (* Since we have Vemurafenib x and MEKInhibitor y, we can apply this logical relation. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, C)\\nImplies(MEK inhibitors are unavailable in the patient's country, any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient)\\n--------\\n\\nDerived Implications:\\n\"}",
            "7 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation: Implies(A, C), which states that if MEK inhibitors are unavailable in the patient\\'s country, then any specific combination treatment involving a MEK inhibitor is unavailable for the patient. *)\\n(* Since we have MEKInhibitor y, we can apply this relation to infer that the combination treatment is unavailable for the patient. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.33265662193298, 'proof tactics': [], 'code': 'theory clinical_94_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u2227 Patient y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u2227 Patient z \u2227 UnavailableIn x y) \u27f6 (Treatment x \u2227 UnavailableFor x z)\"\\n\\n(* Explanation 3: If MEK inhibitors are unavailable in the patient\\'s country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w. (MEKInhibitor x \u2227 Country y \u2227 Patient z \u2227 UnavailableIn x y) \u27f6 (Combination w \u2227 Vemurafenib w \u2227 MEKInhibitor x \u2227 UnavailableFor w z)\"\\n\\n(* Explanation 4: If a specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable in the patient\\'s country, then it is unavailable for the patient *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z w. (Combination w \u2227 Vemurafenib w \u2227 MEKInhibitor x \u2227 Country y \u2227 Patient z \u2227 UnavailableIn w y) \u27f6 UnavailableFor w z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2203x y. Combination x \u2227 Vemurafenib x \u2227 MEKInhibitor y \u2227 UnavailableFor x y\"\\nproof -\\n  (* From the assumption, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 3 provides a logical relation: Implies(A, C), which states that if MEK inhibitors are unavailable in the patient\\'s country, then any specific combination treatment involving a MEK inhibitor is unavailable for the patient. *)\\n  (* Since we have MEKInhibitor y, we can apply this relation to infer that the combination treatment is unavailable for the patient. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  (* Therefore, we can conclude that there exists a combination x and a patient y such that the combination vemurafenib and MEK inhibitor is unavailable for the patient. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, C)\\nImplies(MEK inhibitors are unavailable in the patient's country, any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient)\\n--------\\nImplies(C, C)\\nTrue\\n--------\\n\\nDerived Implications:\\n\"}",
            "8 iteration: {'syntactic validity': True, 'error code': '(* Explanation 4 provides a direct implication: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n(* This matches the logical relation Implies(A, D). *)\\n(* Since we have CombinationVemurafenib x and MEKInhibitor y, we can directly apply this implication. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.3079001903534, 'proof tactics': [], 'code': 'theory clinical_94_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationTreatment :: \"entity \u21d2 bool\"\\n  CombinationVemurafenib :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (Treatment z \u2227 Involves z x \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 3: If MEK inhibitors are unavailable in the patient\\'s country, then any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (CombinationTreatment z \u2227 Involves z x \u2227 Involves z y \u2227 CombinationVemurafenib y \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 4: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_4: \"\u2200x y. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (CombinationVemurafenib x \u2227 MEKInhibitor x \u27f6 UnavailableFor x y)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"CombinationVemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. CombinationVemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the assumption, we have known information about CombinationVemurafenib and MEKInhibitor. *)\\n  from asm have \"CombinationVemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 4 provides a direct implication: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\n  (* This matches the logical relation Implies(A, D). *)\\n  (* Since we have CombinationVemurafenib x and MEKInhibitor y, we can directly apply this implication. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient (from Explanatory Sentence 3)\\nD: the combination of vemurafenib and a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, C)\\nImplies(MEK inhibitors are unavailable in the patient's country, any specific combination treatment involving a MEK inhibitor, such as the combination of vemurafenib and a MEK inhibitor, is unavailable for the patient)\\n--------\\nImplies(A, D)\\nImplies(MEK inhibitors are unavailable in the patient's country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\n\\nDerived Implications:\\n\"}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a direct implication that if MEK inhibitors are unavailable, then the combination is unavailable. *)\\n(* We use the logical relation Implies(A, C) from Explanation 3. *)\\nthen have \"UnavailableFor x y\" sledgehammer', 'solving time': 103.34513449668884, 'proof tactics': [], 'code': 'theory clinical_94_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationVemurafenib :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor is unavailable for the patient. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (Treatment z \u2227 Involves z x \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 3: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (CombinationVemurafenib z \u2227 Involves z x \u27f6 UnavailableFor z y)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"CombinationVemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient. *)\\n  shows \"\u2200x y. CombinationVemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the assumption, we have a combination of vemurafenib and a MEK inhibitor. *)\\n  from asm have \"CombinationVemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 3 provides a direct implication that if MEK inhibitors are unavailable, then the combination is unavailable. *)\\n  (* We use the logical relation Implies(A, C) from Explanation 3. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: the combination of vemurafenib and a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, C)\\nImplies(MEK inhibitors are unavailable in the patient's country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\n\\nDerived Implications:\\n\"}",
            "10 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 8.702057123184204, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'cvc4: Try this: using explanation_1 explanation_3 by blast (4 ms)', 'verit found a proof...', 'zipperposition: Found duplicate proof', 'cvc4 found a proof...', 'vampire found a proof...', 'verit: Found duplicate proof', 'cvc4: Found duplicate proof', 'zipperposition found a proof...', 'zipperposition: Found duplicate proof', 'cvc4 found a proof...', 'e found a proof...', 'cvc4: Found duplicate proof', 'vampire: Try this: using explanation_1 explanation_3 by force (11 ms)', 'e: Found duplicate proof', 'zipperposition found a proof...', 'zipperposition: Found duplicate proof', 'Done'], 'code': 'theory clinical_94_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Country :: \"entity \u21d2 bool\"\\n  UnavailableIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  UnavailableFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationVemurafenib :: \"entity \u21d2 bool\"\\n  Accessed :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Receive :: \"entity \u21d2 entity \u21d2 bool\"\\n  CombinationTreatment :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: MEK inhibitors are unavailable in the patient\\'s country *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y\"\\n\\n(* Explanation 2: If MEK inhibitors are unavailable in the patient\\'s country, then any treatment involving a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (Treatment z \u2227 Involves z x \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 3: If MEK inhibitors are unavailable in the patient\\'s country, then the combination of vemurafenib and a MEK inhibitor is unavailable for the patient *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. (MEKInhibitor x \u2227 Country y \u27f6 UnavailableIn x y) \u27f6 (CombinationVemurafenib z \u2227 MEKInhibitor x \u27f6 UnavailableFor z y)\"\\n\\n(* Explanation 4: This means that if MEK inhibitors cannot be accessed, the patient cannot receive the combination treatment *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z. (MEKInhibitor x \u27f6 \u00acAccessed x) \u27f6 (Patient y \u27f6 \u00acReceive y z \u2227 CombinationTreatment z)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"CombinationVemurafenib x \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\n  shows \"\u2200x y. CombinationVemurafenib x \u2227 MEKInhibitor y \u27f6 UnavailableFor x y\"\\nproof -\\n  (* From the assumption, we have known information about CombinationVemurafenib and MEKInhibitor. *)\\n  from asm have \"CombinationVemurafenib x \u2227 MEKInhibitor y\" <ATP>\\n  (* Explanation 3 provides a direct implication from MEK inhibitors being unavailable to the combination of vemurafenib and a MEK inhibitor being unavailable. *)\\n  (* There is a logical relation Implies(A, C), Implies(MEK inhibitors are unavailable in the patient\\'s country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient) *)\\n  (* Since we have MEKInhibitor y, we can use explanation_3 to infer UnavailableFor x y. *)\\n  then have \"UnavailableFor x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: MEK inhibitors are unavailable in the patient's country (from Explanatory Sentence 1)\\nB: any treatment involving a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 2)\\nC: the combination of vemurafenib and a MEK inhibitor is unavailable for the patient (from Explanatory Sentence 3)\\nD: the patient cannot receive the combination treatment (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(MEK inhibitors are unavailable in the patient's country, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(A, C)\\nImplies(MEK inhibitors are unavailable in the patient's country, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(MEK inhibitors are unavailable in the patient's country), Not(the patient cannot receive the combination treatment))\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(D))\\nImplies(Not(the combination of vemurafenib and a MEK inhibitor is unavailable for the patient), Not(the patient cannot receive the combination treatment))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(any treatment involving a MEK inhibitor is unavailable for the patient), Not(the patient cannot receive the combination treatment))\\n--------\\nImplies(D, C)\\nImplies(the patient cannot receive the combination treatment, the combination of vemurafenib and a MEK inhibitor is unavailable for the patient)\\n--------\\nImplies(D, B)\\nImplies(the patient cannot receive the combination treatment, any treatment involving a MEK inhibitor is unavailable for the patient)\\n--------\\n\"}"
        ]
    }
}